Cytotoxic T lymphocytes induce caspase-dependent and -independent cell death in neuroblastomas in a MHC-nonrestricted fashion

Journal of Immunology

Volumn 177, Issue 11, 2006, Pages 7540-7550

  De Geer, Anna ^a   Kiessling, Rolf ^a   Levitsky, Victor ^a   Levitskaya, Jelena ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BENZYLOXYCARBONYLVALYLALANYLASPARTYL FLUOROMETHYL KETONE; BENZYLOXYCARBONYLVALYLASPARTYLVALYLALANYLASPARTYL FLUOROMETHYL KETONE; CASPASE; CASPASE INHIBITOR; CD8 ANTIGEN; CYTOKINE RECEPTOR ANTAGONIST; DEATH RECEPTOR 5; ETANERCEPT; GAMMA INTERFERON ANTIBODY; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PROTEIN BCL 2; PROTEIN BCL XL; REAGENT; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; TUMOR NECROSIS FACTOR RECEPTOR 1; UNCLASSIFIED DRUG;

ANTIGEN PRESENTATION; APOPTOSIS; ARTICLE; BYSTANDER EFFECT; CANCER CELL DESTRUCTION; CD8+ T LYMPHOCYTE; CELL DEATH; CELL KILLING; CONTROLLED STUDY; CULTURE MEDIUM; CYTOTOXIC T LYMPHOCYTE; EFFECTOR CELL; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MAJOR HISTOCOMPATIBILITY COMPLEX; NEUROBLASTOMA; NEUROBLASTOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL LINE;

EID: 33751568511     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.177.11.7540     Document Type: Article

References (52)

1. Garcia-Lora, A., I. Algarra, and F. Garrido. 2003. MHC class I antigens, immune surveillance, and tumor immune escape. J. Cell. Physiol. 195: 346-355.
2. Brodeur, G. M., and J. M. Maris. 2002. Neuroblastoma. In Principles and Practice of Pediatric Oncology. P. A. Pizzo and D. G. Poplack, eds. Lippincott Williams & Wilkins, Philadelphia, p. 895-937.
3. Maris, J. M., and K. K. Matthay. 1999. Molecular biology of neuroblastoma. J. Clin. Oncol. 17: 2264-2279.
4. Bolande, R. P. 1991. The spontaneous regression of neuroblastoma. Experimental evidence for a natural host immunity. Pathol. Annu. 26: 187-199.
5. Valteau, D., V. Scott, G. Carcelain, O. Hartmann, B. Escudier, T. Hercend, and F. Triebel. 1996. T-cell receptor repertoire in neuroblastoma patients. Cancer Res. 56: 362-369.
6. Papac, R. J. 1998. Spontaneous regression of cancer: possible mechanisms. In Vivo 12: 571-578.
7. Cheng, N. C., M. Beitsma, A. Chan, I. Op den Camp, A. Westerveld, J. Pronk, and R. Versteeg. 1996. Lack of class I HLA expression in neuroblastoma is associated with high N-myc expression and hypomethylation due to loss of the MEMO-1 locus. Oncogene 13: 1737-1744.
8. Wolfl, M., A. A. Jungbluth, F. Garrido, T. Cabrera, S. Meyen-Southard, R. Spitz, K. Ernestus, and F. Berthold. 2004. Expression of MHC class I, MHC class II, and cancer germline antigens in neuroblastoma. Cancer Immunol. Immunother. 54: 400-406.
9. Teitz, T., J. M. Lahti, and V. J. Kidd. 2001. Aggressive childhood neuroblastomas do not express caspase-8: an important component of programmed cell death. J. Mol. Med. 79: 428-436.
10. Teitz, T., T. Wei, M. B. Valentine, E. F. Vanin, J. Grenet, V. A. Valentine, F. G. Behm, A. T. Look, J. M. Lahti, and V. J. Kidd. 2000. Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN. Nat. Med. 6: 529-535.
11. Prigione, I., M. V. Corrias, I. Airoldi, L. Raffaghello, F. Morandi, P. Bocca, C. Cocco, S. Ferrone, and V. Pistoia. 2004. Immunogenicity of human neuroblastoma. Ann. NY Acad. Sci. 1028: 69-80.
12. Raffaghello, L., I. Prigione, I. Airoldi, M. Camoriano, F. Morandi, P. Bocca, C. Gambini, S. Ferrone, and V. Pistoia. 2005. Mechanisms of immune evasion of human neuroblastoma. Cancer Lett. 228: 155-161.
13. Russell, J. H., and T. J. Ley. 2002. Lymphocyte-mediated cytotoxicity. Annu. Rev. Immunol. 20: 323-370.
14. + T cells in adoptive immunotherapy and the indirect mechanism of tumor rejection. Crit. Rev. Immunol. 20: 17-56.
15. + cytotoxic T-lymphocyte clones. J. Virol. 73: 3623-3629.
16. Rickinson, A. B., and E. Kieff. 2001. Epstein-Barr Virus. In Fields Virology. D. M. Knipe and P. M. Howley, eds. Lippincott Williams & Williams, Philadelphia, p. 2575-2628.
17. Levitsky, V., P. O. de Campos-Lima, T. Frisan, and M. G. Masucci. 1998. The clonal composition of a peptide-specific oligoclonal CTL repertoire selected in response to persistent EBV infection is stable over time. J. Immunol. 161: 594-601.
18. Alexander, J., J. A. Payne, R. Murray, J. A. Frelinger, and P. Cresswell. 1989. Differential transport requirements of HLA and H-2 class I glycoproteins. Immunogenetics 29: 380-388.
19. Vertuani, S., A. De Geer, V. Levitsky, P. Kogner, R. Kiessling, and J. Levitskaya. 2003. Retinoids act as multistep modulators of the major histocompatibility class I presentation pathway and sensitize neuroblastomas to cytotoxic lymphocytes. Cancer Res. 63: 8006-8013.
20. Hallermalm, K., A. De Geer, R. Kiessling, V. Levitsky, and J. Levitskaya. 2004. Autocrine secretion of Fas ligand shields tumor cells from Fas-mediated killing by cytotoxic lymphocytes. Cancer Res. 64: 6775-6782.
21. Schneider, P., and J. Tschopp. 2000. Apoptosis induced by death receptors. Pharm. Acta Helv. 74: 281-286.
22. Walczak, H., and P. H. Krammer. 2000. The CD95 (APO-1/Fas) and the TRAIL (APO-2L) apoptosis systems. Exp. Cell Res. 256: 58-66.
23. Yang, X., M. S. Merchant, M. E. Romero, M. Tsokos, L. H. Wexler, U. Kontny, C. L. Mackall, and C. J. Thiele. 2003. Induction of caspase 8 by interferon γ renders some neuroblastoma (NB) cells sensitive to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) but reveals that a lack of membrane TR1/TR2 also contributes to TRAIL resistance in NB. Cancer Res. 63: 1122-1129.
24. Sidoti-de Fraisse, C., V. Rincheval, Y. Risler, B. Mignotte, and J. L. Vayssiere. 1998. TNF-α activates at least two apoptotic signaling cascades. Oncogene 17: 1639-1651.
25. Leist, M., and M. Jaattela. 2001. Four deaths and a funeral: from caspases to alternative mechanisms. Nat. Rev. Mol. Cell Biol. 2: 589-598.
26. Maianski, N. A., D. Roos, and T. W. Kuijpers. 2003. Tumor necrosis factor α induces a caspase-independent death pathway in human neutrophils. Blood 101: 1987-1995.
27. Ekert, P. G., J. Silke, and D. L. Vaux. 1999. Caspase inhibitors. Cell Death Differ. 6: 1081-1086.
28. Zhivotovsky, B., and S. Orrenius. 2005. Caspase-2 function in response to DNA damage. Biochem. Biophys. Res. Commun. 331: 859-867.
29. Zeh, H. J., III, and M. T. Lotze. 2005. Addicted to death: invasive cancer and the immune response to unscheduled cell death. J. Immunother. 28: 1-9.
30. L sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis. Mol. Cell 8: 705-711.
31. Hopkins-Donaldson, S., J. L. Bodmer, K. B. Bourloud, C. B. Brognara, J. Tschopp, and N. Gross. 2000. Loss of caspase-8 expression in highly malignant human neuroblastoma cells correlates with resistance to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Cancer Res. 60: 4315-4319.
32. Hopkins-Donaldson, S., J. L. Bodmer, K. B. Bourloud, C. B. Brognara, J. Tschopp, and N. Gross. 2000. Loss of caspase-8 expression in neuroblastoma is related to malignancy and resistance to TRAIL-induced apoptosis. Med. Pediatr. Oncol. 35: 608-611.
33. Stupack, D. G., T. Teitz, M. D. Potter, D. Mikolon, P. J. Houghton, V. J. Kidd, J. M. Lahti, and D. A. Cheresh. 2006. Potentiation of neuroblastoma metastasis by loss of caspase-8. Nature 439: 95-99.
34. Takita, J., H. W. Yang, F. Bessho, R. Kanada, K. Yamamoto, V. Kidd, T. Teitz, T. Wei, and Y. Hayashi. 2000. Absent or reduced expression of the caspase 8 gene occurs frequently in neuroblastoma, but not commonly in Ewing sarcoma or rhabdomyosarcoma. Med. Pediatr. Oncol. 35: 541-543.
35. Yu, L., A. Alva, H. Su, P. Dutt, E. Freundt, S. Welsh, E. H. Baehrecke, and M. J. Lenardo. 2004. Regulation of an ATG7-beclin 1 program of autophagic cell death by caspase-8. Science 304: 1500-1502.
36. Foghsgaard, L., D. Wissing, D. Mauch, U. Lademann, L. Bastholm, M. Boes, F. Elling, M. Leist, and M. Jaattela. 2001. Cathepsin B acts as a dominant execution protease in tumor cell apoptosis induced by tumor necrosis factor. J. Cell Biol. 153: 999-1010.
37. Li, J., Q. Li, C. Xie, H. Zhou, Y. Wang, N. Zhang, H. Shao, S. C. Chan, X. Peng, S. C. Lin, and J. Han. 2004. β-Actin is required for mitochondria clustering and ROS generation in TNF-induced, caspase-independent cell death. J. Cell Sci. 117: 4673-4680.
38. Broker, L. E., F. A. Kruyt, and G. Giaccone. 2005. Cell death independent of caspases: a review. Clin. Cancer Res. 11: 3155-3162.
39. Kroemer, G., and S. J. Martin. 2005. Caspase-independent cell death. Nat. Med. 11: 725-730.
40. Pohle, T., S. Brandlein, N. Ruoff, H. K. Muller-Hermelink, and H. P. Vollmers. 2004. Lipoptosis: tumor-specific cell death by antibody-induced intracellular lipid accumulation. Cancer Res. 64: 3900-3906.
41. Kitanaka, C., K. Kato, R. Ijiri, K. Sakurada, A. Tomiyama, K. Noguchi, Y. Nagashima, A. Nakagawara, T. Momoi, Y. Toyoda, et al. 2002. Increased Ras expression and caspase-independent neuroblastoma cell death: possible mechanism of spontaneous neuroblastoma regression. J. Natl. Cancer Inst. 94: 358-368.
42. Biederbick, A., H. F. Kern, and H. P. Elsasser. 1995. Monodansylcadaverine (MDC) is a specific in vivo marker for autophagic vacuoles. Eur J. Cell Biol. 66: 3-14.
43. Mizushima, N. 2004. Methods for monitoring autophagy. Int. J. Biochem. Cell Biol. 36: 2491-2502.
44. Lotze, M. T., and R. A. DeMarco. 2003. Dealing with death: HMGB1 as a novel target for cancer therapy. Curr. Opin. Investig. Drugs. 4: 1405-1409.
45. Fink, S. L., and B. T. Cookson. 2005. Apoptosis, pyroptosis, and necrosis: mechanistic description of dead and dying eukaryotic cells. Infect. Immun. 73: 1907-1916.
46. Oue, T., M. Fukuzawa, T. Kusafuka, Y. Kohmoto, K. Imura, S. Nagahara, and A. Okada. 1996. In situ detection of DNA fragmentation and expression of bcl-2 in human neuroblastoma: relation to apoptosis and spontaneous regression. J. Pediatr. Surg. 31: 251-257.
47. Rossig, C., C. M. Bollard, J. G. Nuchtern, D. A. Merchant, and M. K. Brenner. 2001. Targeting of G(D2)-positive tumor cells by human T lymphocytes engineered to express chimeric T-cell receptor genes. Int. J. Cancer 94: 228-236.
48. Rossig, C., C. M. Bollard, J. G. Nuchtern, C. M. Rooney, and M. K. Brenner. 2002. Epstein-Barr virus-specific human T lymphocytes expressing antitumor chimeric T-cell receptors: potential for improved immunotherapy. Blood 99: 2009-2016.
49. Gonzalez, S., A. Naranjo, L. M. Serrano, W. C. Chang, C. L. Wright, and M. C. Jensen. 2004. Genetic engineering of cytolytic T lymphocytes for adoptive T-cell therapy of neuroblastoma. J. Gene Med. 6: 704-711.
50. Manzke, O., O. Russello, C. Leenen, V. Diehl, H. Bohlen, and F. Berthold. 2001. Immunotherapeutic strategies in neuroblastoma: antitumoral activity of deglycosylated ricin A conjugated anti-GD2 antibodies and anti-CD3Xanti-GD2 bispecific antibodies. Med. Pediatr. Oncol. 36: 185-189.
51. Jensen, M., K. Ernestus, J. Kemshead, M. Klehr, M. S. Von Bergwelt-Baildon, T. Schinkothe, J. L. Schultze, and F. Berthold. 2003. The bi-specific CD3 X NCAM antibody: a model to preactivate T cells prior to tumour cell lysis. Clin. Exp. Immunol. 134: 253-263.
52. Sabri, F., F. Chiodi, J. P. Piret, C. H. Wei, E. Major, B. Westermark, M. G. Masucci, and V. Levitsky. 2003. Soluble factors released by virus specific activated cytotoxic T-lymphocytes induce apoptotic death of astroglioma cell lines. Brain Pathol. 13: 165-175.